Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis
NCT01841411 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2013-04-26
Summary
N-Acetyl cysteine (NAC) is an amino acid with strong antioxidant, mucolytic and antibacterial properties, and is produced within the human body.Its effect in biofilms has been tested in several bacteria. Biofilms have recently been observed in 90% of subjects with bacterial vaginosis (BV) with Gardnerella vaginalis being the predominant species. Although a wide range of antimicrobial agents are currently available, treatment options for controlling BV are still limited. Furthermore, the number of relapses are increasing and require alternative treatments. This study is aiming to evaluate the role of NAC in treatment of BV and prevention of recurrence.
Conditions
- Bacterial Vaginosis
Interventions
- DRUG
-
N-Acetyl cysteine
N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
- DRUG
-
Metronidazole + N-Acetyl cysteine
Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
- DRUG
-
metronidazole
Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
Sponsors & Collaborators
-
Minia University
lead OTHER
Principal Investigators
-
Ahmed R El-Adawy, Professor · Minia university hopital of gynecology and obstetrics
-
Heba A Mohamed, MSc · Minia University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2013-06-30
- Completion
- 2013-06-30
Countries
- Egypt
Study Locations
More Related Trials
-
The Mediterranean Diet and Bacterial Vaginitis
NCT05828498 ·Status: COMPLETED
-
Report of a New Method Used to Identify the Bacteria Present in a Human Colon Biopsy Sample
NCT00882752 ·Status: COMPLETED
-
Empirical Intravenous Beta-Lactam Plus Metronidazole Vs Oral Cefixime Plus Metronidazole for the Treatment of Liver Abscess
NCT06847126 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Human Microbiota in Healthy and Pathological Conditions
NCT03460392 ·Status: UNKNOWN
-
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
NCT01445678 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Levornidazole Disodium Phosphate for Injection vs. Ornidazole in Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria
NCT06828874 ·Status: COMPLETED ·Phase: PHASE4
-
Antimicrobial Resistance Rate In Escherichia Coli And Klebsiella Pneumonia : A Retrospective Study
NCT04196387 ·Status: COMPLETED
-
Characterization of Enterococci
NCT04777240 ·Status: COMPLETED
-
Baseline Study of Vaginal Microbiota in Healthy Chinses Female Population
NCT04887636 ·Status: COMPLETED
-
Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections
NCT00860587 ·Status: UNKNOWN
-
Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals
NCT06252428 ·Status: COMPLETED
-
Detection of Anaerobes in Different Clinicalsamples
NCT03266341 ·Status: UNKNOWN
-
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
NCT01324726 ·Status: COMPLETED
-
A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
NCT00952796 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention and Decolonization of Multidrug-resistant Bacteria With Probiotics
NCT03967301 ·Status: UNKNOWN ·Phase: NA
-
Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
NCT00629135 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)
NCT00481702 ·Status: COMPLETED ·Phase: PHASE3
-
Microbial Epidemiology and Chlorhexidine Suscebtibily of Oropharyngeal and Intestinal Colonization
NCT02840656 ·Status: COMPLETED
-
Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections
NCT04628572 ·Status: COMPLETED
-
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)
NCT00769171 ·Status: COMPLETED ·Phase: PHASE3
-
Longitudinal Surveillance of Rectal Colonization and Transmission by Resistant Bacteria in Acutely Decompensated Cirrhosis
NCT06511492 ·Status: NOT_YET_RECRUITING
-
Identification of Clostridium Butyricum and Clostridium Neonatal in the Digestive Microbiota of Premature Infants Before 34 Weeks and Developing or Not Ulcerative Necrotizing Enterocolitis (NEC) During Hospitalization
NCT04584320 ·Status: ACTIVE_NOT_RECRUITING
-
Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections
NCT01147640 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread
NCT02666274 ·Status: UNKNOWN
-
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
NCT01726023 ·Status: COMPLETED ·Phase: PHASE3